Varian invests in hydrogel tech to enhance prostate radiotherapy
This article was originally published in Clinica
Executive Summary
Varian Medical Systems is investing $15m in Augmenix, a company developing a hydrogel product to improve efficacy in prostate radiotherapy. The deal gives Varian a minority stake and includes an option for the company to acquire Augmenix outright, subject to the achievement of certain milestones.